Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Mechlorethamine: A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.Hodgkin Disease: A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.Lomustine: An alkylating agent of value against both hematologic malignancies and solid tumors.Vincristine: An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)Radiotherapy: The use of IONIZING RADIATION to treat malignant NEOPLASMS and some benign conditions.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Radiotherapy Dosage: The total amount of radiation absorbed by tissues as a result of radiotherapy.Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.Actuarial Analysis: The application of probability and statistical methods to calculate the risk of occurrence of any event, such as onset of illness, recurrent disease, hospitalization, disability, or death. It may include calculation of the anticipated money costs of such events and of the premiums necessary to provide for payment of such costs.Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Lung Neoplasms: Tumors or cancer of the LUNG.Radiotherapy, Adjuvant: Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Doxorubicin: Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Chemotherapy, Adjuvant: Drug therapy given to augment or stimulate some other form of treatment such as surgery or radiation therapy. Adjuvant chemotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Clinical Trials as Topic: Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Diagnostic Imaging: Any visual display of structural or functional patterns of organs or tissues for diagnostic evaluation. It includes measuring physiologic and metabolic responses to physical and chemical stimuli, as well as ultramicroscopy.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
combined modality therapyCOMBINED MODALITY THERAPY. Todd Wasserman; Fiscal Year: 1990. ..b>Combined modality therapy is in wide clinical use for the ... INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose ... OPTIMIZATION OF RADIATION THERAPY. LYLE DETHLEFSEN; Fiscal Year: 1980. *COMBINED MODALITY THERAPY. Todd Wasserman; Fiscal Year ... and toxicity of combined-modality therapy using high-dose (64.8 Gy) versus standard-dose (50.4 Gy) radiation therapy for the ...
Pancreatic Cancer | Doctors HospitalCombined Modality Therapy. Most times, pancreatic cancer is discovered at an advanced stage. Surgery may not be appropriate in ... Radiation Therapy. This is the use of radiation to kill cancer cells and shrink tumors. Radiation therapy may be: *External- ... The physical exam combined with all of your test results, will help to determine the stage of cancer you have. Staging is used ... Biological Therapy. The use of medications or substances made by the body. They can increase or restore the body's natural ...
Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer - Full Text View -...Not a candidate for combined modality therapy. *No cavitary lesions. Exclusion Criteria:. *Evidence of symptomatic or untreated ... Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer. The recruitment ... This Phase II Trial is Studying Sunitinib to See How Well it Works When Given as Maintenance Therapy in Treating Patients With ... PURPOSE: This phase II trial is studying sunitinib to see how well it works when given as maintenance therapy in treating ...
Disulfiram, an option for the treatment of pathological gambling?Behavior Therapy. Combined Modality Therapy. Comorbidity. Disulfiram / adverse effects, therapeutic use*. Follow-Up Studies. ... 6114909 - Long-term prognosis of behavior therapy in practice.. 11940799 - A prospective follow-up study of cognitive functions ... after electroconvulsive therapy.. 23353589 - Epidural anesthesia followed by epidural analgesia produces less inflammatory ...
Combined endovascular and vascular surgical therapy of a blister-like distal internal carotid aneurysm in a patient with a...Combined Modality Therapy. Embolization, Therapeutic*. Endovascular Procedures*. Humans. Intracranial Aneurysm / complications ... Combined endovascular and vascular surgical therapy of a blister-like distal internal carotid aneurysm in a patient with a ... radiography, surgery, therapy*. Magnetic Resonance Angiography. Male. Subarachnoid Hemorrhage / etiology, therapy. Tomography, ... left internal carotid artery with a right-sided aortic arch treated with combined endovascular and vascular surgical therapy. ...
Differential effects of treatments for chronic depression: a latent growth model reanalysis.Cognitive Therapy*. Combined Modality Therapy. Depressive Disorder, Major / diagnosis, psychology, therapy*. Dysthymic Disorder ... Next Document: Interpersonal accuracy of interventions and the outcome of cognitive and interpersonal therapies for.... ... diagnosis, psychology, therapy*. Female. Humans. Male. Middle Aged. Models, Psychological. Personality Inventory / statistics ...
Osteonecrosis of the jaw related to sunitinib.Combined Modality Therapy. Humans. Indoles / adverse effects*, therapeutic use. Kidney Neoplasms / drug therapy*, surgery. Male ... After initial therapy with interferon and vinblastine, a relapse occurred and the therapy was changed to sorafenib, followed by ... Neoplasm Recurrence, Local / drug therapy*, surgery. Nephrectomy. Osteonecrosis / chemically induced*, diagnosis, surgery. ... Osteonecrosis of the lower jaw appeared 1 year after initial and exclusive therapy with sunitinib.. CONCLUSIONS: ...
Transurethral injection of bulking agent for treatment of failed mid-urethral sling procedures.Combined Modality Therapy. Dimethylpolysiloxanes / administration & dosage, adverse effects, therapeutic use*. Equipment ... 8730245 - Treatment of helicobacter pylori infection with low or high dose omeprazole combined wi.... 11720675 - A treatment ...
Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts.Combined Modality Therapy. Comorbidity. Diabetes Mellitus / epidemiology. Female. Follow-Up Studies. Humans. Male. Middle Aged ... Myocardial Infarction / drug therapy, mortality*, therapy. Prognosis. Proportional Hazards Models. Recurrence. Risk. Time ... Therefore, all efforts should be made to shorten the total ischemic time, not only for thrombolytic therapy but also for ... 11174818 - Selecting patients for combined femorofemoral bypass grafting and iliac balloon angiopl.... 11797968 - Angioplasty ...
Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus...Combined Modality Therapy. Coronary Disease / drug therapy*, surgery*. Female. Humans. Male. Middle Aged. Myocardial ... treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy ...
Ludwig's angina: case report and review.Combined Modality Therapy. Drainage. Emergency Service, Hospital. Female. Humans. Ludwig's Angina* / diagnosis, etiology, ... A typical case of Ludwig's angina is presented, followed by a review of clinical findings and therapeutic modalities. Emphasis ...
Additional salutary effects of the combination of exercise training and an angiotensin-converting enzyme inhibitor on the...Combined Modality Therapy. Hypertension / drug therapy*, pathology, physiopathology, therapy*. Hypertrophy, Left Ventricular / ... drug therapy, pathology, therapy. Lisinopril / therapeutic use. Male. Physical Conditioning, Animal*. Rats. Rats, Inbred SHR. ... Combining exercise training with lisinopril treatment increased %FS by 25%, decreased the E/A ratio and Edec slope by 35% and ... when combined with moderate exercise training, is more promising in attenuating cardiac dysfunction than either agent alone in ...
Effect of volume recruitment on response to surfactant treatment in rabbits with lung injury.Combined Modality Therapy. Disease Models, Animal. Drug Evaluation, Preclinical. Functional Residual Capacity / drug effects. ...
Cases of human envenoming caused by Philodryas olfersii and Philodryas patagoniensis (Serpentes: Colubridae).Combined Modality Therapy. Female. Humans. Poisoning / diagnosis, therapy. Snake Bites / diagnosis*, therapy. Snake Venoms / ...
Sucralfate for the prevention of early rebleeding following injection sclerotherapy for esophageal varices.Combined Modality Therapy. Esophageal Diseases / etiology. Esophageal and Gastric Varices / etiology, mortality, therapy*. ... Gastrointestinal Hemorrhage / etiology, mortality, therapy*. Humans. Liver Diseases / complications, pathology. Male. Middle ...
Treatment of severe acute respiratory distress syndrome: a final report on a phase I study.Its only effective treatment is respiratory therapy. If this fails mortality is probably 100 per cent. No other treatment for ... Combined Modality Therapy. Female. Humans. Male. Middle Aged. Multiple Trauma / complications. Oxygen / blood. Plasminogen ... Its only effective treatment is respiratory therapy. If this fails mortality is probably 100 per cent. No other treatment for ... Respiratory Distress Syndrome, Adult / complications, drug therapy*, metabolism, mortality. Sepsis / complications. Severity of ...
Malignant cerebral glioma-I: Survival, disability, and morbidity after radiotherapy | The BMJCombined modality therapy of operated astrocytomas grades III and IV. Confirmation of the value of postoperative irradiation ... In: Brain tumours: scientific basis, clinical investigation and current therapy. In: Thomas DGT, Graham DI eds. London: ... Radiation therapy for neoplasms of the brain. J Neurosurg 1987;66:1-22. ... Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary ...
Prophylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infants.Surfactant therapy is effective in improving the outcome of very preterm infants. Trials have studied a wide variety of ... Combined Modality Therapy / methods. Continuous Positive Airway Pressure / methods*. Humans. Infant, Newborn. Infant, Premature ... BACKGROUND: Surfactant therapy is effective in improving the outcome of very preterm infants. Trials have studied a wide ...
Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease - Full...The combined modality should consist of either:. *induction (2 cycles) chemotherapy followed by concurrent chemo-radiation ... Undergone lung cancer specific therapy (including surgery) prior to primary chemo-radiation therapy ... Primary therapy should be a minimum of 2 cycles of Platinum-based first-line chemotherapy, given concurrent with thoracic ... Subjects must have completed the primary therapy at least 4 weeks and no later than 6 months prior to study entry ...
International Journal of Clinical Oncology, Volume 17, Issue 5 - SpringerCombined modality therapy for laryngeal cancer with superselective intra-arterial cisplatin infusion and concomitant ... Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a ... Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in ... or high-risk breast cancer treated using upfront modified radical mastectomy with or without post-mastectomy radiation therapy ...
https://www.cancer.gov/types/brain/hp/adult-brain-treatment-pdqFor glioblastoma, combined modality therapy with resection, radiation, and chemotherapy is standard. Anaplastic astrocytomas, ... The three trials were combined in a trial-level meta-analysis. The combined analysis showed the following: * The combined ... combined modality treatment may be considered, using surgical resection followed by radiation therapy. However, the published ... Mean OS in the combined-therapy group was 5.7 months, and mean OS in the WBRT-alone group was 6.5 months (P = .14).. *In the ...
Articles related to 24035327 - PubMed - NCBICisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index. Hung A, et al. Cancer. 2003 ... Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Clinical trial ...
Oesophageal cancer | Nature Reviews Disease PrimersINT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose ... Initial results of CALGB 80803 (Alliance): a randomized phase II trial of PET scan-directed combined modality therapy for ... Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5- ... Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. . Med. J. Aust. 180, 387- ...
All About Head and Neck Cancers | OncoLinkPosner M. Evolving strategies for combined-modality therapy for locally advanced head and neck cancer. Oncologist. 12(8):967-74 ... Proton therapy is another type of radiation therapy that is being used to treat head and neck cancers. The main difference ... Chemotherapy is commonly given in conjunction with radiation therapy. This is referred to as chemoradiation therapy. In this ... Radiation Therapy. Radiation is the use of high-energy x-rays to kill the tumor. This treatment is very complex and should be ...
Diagnosis and Management of Generalized Anxiety Disorder and Panic Disorder in Adults - American Family PhysicianSuccessful outcomes may require a combination of treatment modalities tailored to the individual patient. Treatment often ... Among psychotherapeutic treatments, cognitive behavior therapy has been studied widely and has an extensive evidence base. ... Screening and monitoring tools can be used to help make the diagnosis and monitor response to therapy. The GAD-7 and the ... Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders. Curr Opin Psychiatry. 2007;20(1):30-35. ...
Plus itOverview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993; 85: 95-111. ... In spite of initial aggressive therapy for HNSCC patients with advanced disease, local recurrence rates are upwards of 60% and ... In spite of aggressive therapy, locoregional disease recurs in 60% and metastatic disease develops in 15% to 25% of patients ... kinase Cε is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anti-cancer therapy ...
Abscopal effect: The abscopal effect is a phenomenon in the treatment of metastatic cancer where localized treatment of a tumor causes not only a shrinking of the treated tumor but also a shrinking of tumors in different compartments from the treated tumor. Initially associated with single-tumor, localized radiation therapy, the term has also come to encompass other types of localized treatments such as electroporation and intra-tumoral injection of therapeutics.ProcarbazineNodular lymphocyte predominant Hodgkin's lymphomaLow-dose chemotherapy: Low-dose chemotherapy is being studied/used in the treatment of cancer to avoid the side effects of conventional chemotherapy. Historically, oncologists have used the highest possible dose that the body can tolerate in order to kill as many cancer cells as possible.External beam radiotherapySmall-cell carcinomaTargeted therapy of lung cancer: Targeted therapy of lung cancer refers to using agents specifically designed to selectively target molecular pathways responsible for, or that substantially drive, the malignant phenotype of lung cancer cells, and as a consequence of this (relative) selectivity, cause fewer toxic effects on normal cells.ABCD rating: ABCD rating, also called the Jewett staging system or the Whitmore-Jewett staging system, is a staging system for prostate cancer that uses the letters A, B, C, and D.DoxorubicinLipoplatin: Lipoplatin (Liposomal cisplatin) is a nanoparticle of 110 nm average diameter composed of lipids and cisplatin. This new drug has successfully finished Phase I, Phase II and Phase III human clinical trials (2,3).Community-based clinical trial: Community-based clinical trials are clinical trials conducted directly through doctors and clinics rather than academic research facilities. They are designed to be administered through primary care physicians, community health centers and local outpatient facilities.Cancer survival rates: Cancer survival rates vary by the type of cancer, stage at diagnosis, treatment given and many other factors, including country. In general survival rates are improving, although more so for some cancers than others.Adenocarcinoma of the lung: Adenocarcinoma of the lung (pulmonary adenocarcinoma) is a common histological form of lung cancer that contains certain distinct malignant tissue architectural, cytological, or molecular features, including gland and/or duct formation and/or production of significant amounts of mucus.Clinical endpoint: In a clinical research trial, a clinical endpoint generally refers to occurrence of a disease, symptom, sign or laboratory abnormality that constitutes one of the target outcomes of the trial, but may also refer to any such disease or sign that strongly motivates the withdrawal of that individual or entity from the trial, then often termed humane (clinical) endpoint.PemetrexedHyperintensityDense artery sign: In medicine, the dense artery sign or hyperdense artery sign is a radiologic sign seen on computer tomography (CT) scans suggestive of early ischemic stroke. In earlier studies of medical imaging in patients with strokes, it was the earliest sign of ischemic stroke in a significant minority of cases.
(1/14907) Adenoviral gene transfer into the normal and injured spinal cord: enhanced transgene stability by combined administration of temperature-sensitive virus and transient immune blockade.
This study characterized gene transfer into both normal and injured adult rat dorsal spinal cord using first (E1-/E3-) or second (E1-/E2A125/E3-, temperature-sensitive; ts) generation of replication-defective adenoviral (Ad) vectors. A novel immunosuppressive regimen aimed at blocking CD4/CD45 lymphocytic receptors was tested for improving transgene persistence. In addition, the effect of gene transfer on nociception was also evaluated. Seven days after treatment, numerous LacZ-positive cells were observed after transfection with either viral vector. By 21 days after transfection, beta-galactosidase staining was reduced and suggestive of ongoing cytopathology in both Ad-treated groups, despite the fact that the immunogenicity of LacZ/Adts appeared less when compared with that elicited by the LacZ/Ad vector. In contrast, immunosuppressed animals showed a significant (P < or = 0.05) increase in the number of LacZ-positive cells not displaying cytopathology. In these animals, a concomitant reduction in numbers of macrophages/microglia and CD4 and CD8 lymphocytes was observed. Only animals that received LacZ/Adts and immunosuppression showed transgene expression after 60 days. Similar results were observed in animals in which the L4-L5 dorsal roots were lesioned before transfection. Gene transfer into the dorsal spinal cord did not affect nociception, independent of the adenovirus vector. These results indicate that immune blockade of the CD4/CD45 lymphocytic receptors enhanced transgene stability in adult animals with normal or injured spinal cords and that persistent transgene expression in the spinal cord does not interfere with normal neural function. (+info)
(2/14907) Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine.
Interleukin-12 (IL-12) is a potent antitumor cytokine, which induces and enhances the activity of natural killer (NK) cells, lymphokine activated killer (LAK) cells and cytotoxic T lymphocytes (CTL). IL-12 also stimulates IFN-gamma production from both T cells and NK cells. In this study, we transfected methylcholanthrene-induced fibrosarcoma (MCA-D) with TNF gene and investigated the therapeutic effect of TNF gene-transduced cancer vaccine and whether the vaccination effect is enhanced by systemic administration of recombinant IL-12 (rIL-12), in a murine model. TNF gene-transduced cancer vaccine or systemic administration of rIL-12 showed slight or moderate inhibition of pre-established tumor. However, simultaneous application of the vaccine and rIL-12 resulted in complete eradication. The cytotoxicity of CTL against parental tumor cells was enhanced with the combination of the vaccine and rIL-12, and IFN-gamma production from spleen cells also increased synergistically. Our findings show that synergistic enhancement of CTL activity and IFN-gamma production could play an important role in the antitumor effect of combination therapy using TNF gene-transduced cancer vaccine and rIL-12. (+info)
(3/14907) Reirradiation combined with hyperthermia in recurrent breast cancer results in a worthwhile local palliation.
Both experimental and clinical research have shown that hyperthermia (HT) gives valuable additional effects when applied in combination with radiotherapy (RT). The purpose of this study was evaluation of results in patients with recurrent breast cancer, treated at the Daniel den Hoed Cancer Center (DHCC) with reirradiation (re-RT; eight fractions of 4 Gy twice weekly) combined with HT. All 134 patients for whom such treatment was planned were included in the analysis. The complete response rate in 119 patients with macroscopic tumour was 71%. Including the 15 patients with microscopic disease, the local control rate was 73%. The median duration of local control was 32 months, and toxicity was acceptable. The complete response (CR) rate was higher, and the toxicity was less with the later developed 433-MHz HT technique compared with the 2450-MHz technique used initially. With this relatively well-tolerated treatment, palliation by local tumour control of a worthwhile duration is achieved in the majority of patients. The technique used for hyperthermia appeared to influence the achieved results. The value of HT in addition to this re-RT schedule has been confirmed by a prospective randomized trial in a similar patient group. In The Netherlands, this combined treatment is offered as standard to patients with breast cancer recurring in previously irradiated areas. (+info)
(4/14907) A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss.
The use of megestrol acetate in the treatment of weight loss in gastrointestinal cancer patients has been disappointing. The aim of the present study was to compare the combination of megestrol acetate and placebo with megestrol acetate and ibuprofen in the treatment of weight loss in such patients. At baseline, 4-6 weeks and 12 weeks, patients underwent measurements of anthropometry, concentrations of albumin and C-reactive protein and assessment of appetite, performance status and quality of life using EuroQol-EQ-5D and EORTC QLQ-C30. Thirty-eight and 35 patients (median weight loss 18%) were randomized to megestrol acetate/placebo or megestrol acetate/ibuprofen, respectively, for 12 weeks. Forty-six (63%) of patients failed to complete the 12-week assessment. Of those evaluable at 12 weeks, there was a decrease in weight (median 2.8 kg) in the megestrol acetate/placebo group compared with an increase (median 2.3 kg) in the megestrol acetate/ibuprofen group (P<0.001). There was also an improvement in the EuroQol-EQ-5D quality of life scores of the latter group (P<0.05). The combination of megestrol acetate/ibuprofen appeared to reverse weight loss and appeared to improve quality of life in patients with advanced gastrointestinal cancer. Further trials of this novel regimen in weight-losing patients with hormone-insensitive cancers are warranted. (+info)
(5/14907) The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients.
We analysed 57 patients with non-myeloid malignancies who received a non-purged autologous PBSCT. All had similar mobilisation and conditioning regimens. A high prior chemotherapy score and the number of chemotherapy lines used (P = 0.015 and P = 0.01, respectively) were adverse predictors of CD34 cell yields. Lower CD34 values (P = 0.002) were seen in patients treated with potent stem cell toxins (BCNU, melphalan, CCNU and mustine), designated toxicity factor 4 agents (TF4). All patients infused with grafts containing CD34 cell doses between 1.0 and 2.0 x 10(6)/kg (range 1.25-1.90) engrafted by day 51. The only variable associated with slow platelet recovery was exposure to TF4 (P = 0.007). The majority of patients with CD34 >1.0 x 10(6)/kg achieved rapid and sustained engraftment and the only predictive factor of delayed recovery is prior exposure to stem cell toxins. Potential PBSCT candidates should if possible avoid first line and salvage chemotherapy containing TF4 drugs. We therefore advocate a minimum CD34 threshold of >1.0 x 10(6)/kg in patients without extensive prior chemoradiotherapy, and > or = 2.0 x 10(6)/kg in all other patients. (+info)
(6/14907) Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
The effect of an extensive prophylactic antimicrobial regimen was prospectively assessed in 126 patients after high-dose chemotherapy and autologous PBSC. They received ciprofloxacin (500 mg/12 h), acyclovir (200 mg/6 h), and itraconazole (200 mg/12 h) orally until neutrophil recovery. Febrile patients received i.v. imipenem (500 mg/6 h) to which vancomycin and amikacin were added if fever persisted for 2-3 and 5 days, respectively. Amphotericin B lipid complex was further given on day 7 or 8 of fever. Median times for a neutrophil count of >0.5 x 10(9)/l and a platelet count of >20 x 10(9)/l were 9 and 11 days. Severe neutropenia (<0.1 x 10(9)/l) lasted for a median of 5 days in which 72% of febrile episodes and 50% of cases of bacteremia occurred. Gram-positive bacteria were isolated in 30 of 40 episodes of bacteremia, 25 of which were caused by Staphylococcus epidermidis. Clinical foci were the intravascular catheter in 35 cases, respiratory infection in 11, cellulitis in two, anal abscess in one, and neutropenic enterocolitis in one. The high incidence of febrile episodes (94%) and bacteremias (31%) may be due to the lack of efficacy of antimicrobial prophylaxis and the persistence of a 5-day period of severe neutropenia. (+info)
(7/14907) Lymphomatoid granulomatosis following autologous stem cell transplantation.
Lymphomatoid granulomatosis (LYG) is a rare angio-destructive lymphoproliferative disorder (LPD) of uncertain etiology, with prominent pulmonary involvement. Recent studies indicate that LYG is an Epstein-Barr virus (EBV)-associated B cell LPD with large numbers of background reactive T lymphocytes (T cell-rich B cell lymphoma). Although the disease frequently, but not exclusively, occurs in various immunodeficiency states, it has not been reported in association with the transient immunosuppression following autologous bone marrow/peripheral stem cell transplantation (ABM/PSCT). We describe a patient who developed lymphomatoid granulomatosis of the lung approximately 2 weeks after high-dose chemotherapy and autologous peripheral stem cell transplantation for multiple myeloma. Although molecular studies showed no evidence of EBV genome in the biopsy material, the serologic profile with high IgM titers was suggestive of primary EBV infection. Complete radiologic remission occurred following reconstitution of the patient's immune response after a 2-week course of ganciclovir treatment. Despite the apparently low frequency of LPD (both LYG and EBV-associated post-transplant lymphoma) in the ABMT setting, we believe that it should be considered in the differential diagnosis of patients whose clinical course following ABMT is complicated by fevers, in the absence of an identifiable infectious process. (+info)
(8/14907) Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
5-Fluorouracil (5-FU) is an effective enhancer of radiation therapy (RT) in head and neck cancers. Due to rapid, predominantly hepatic metabolism by dihydropyrimidine dehydrogenase (DPD) and suggested clinical benefit from prolonged drug exposure, 5-FU is commonly given by continuous infusion. Eniluracil is a novel DPD-inactivator designed to prolong the half-life of 5-FU and provide sustained plasma concentrations of 5-FU with oral dosing. We conducted a Phase I study of the safety and efficacy of eniluracil given with oral 5-FU in patients receiving concurrent RT for recurrent or advanced squamous cell carcinomas of the head and neck. Thirteen patients with recurrent, metastatic, or high-risk (defined as an expected 2-year survival rate of <10%) head and neck cancer were enrolled and treated with concomitant chemoradiotherapy on an every-other-week schedule. Eniluracil at a fixed dose [20 mg twice a day (BID)] was given for 7 consecutive days (days 1-7). 5-FU and RT were given on 5 consecutive days (days 2-6). One patient was treated with once-daily RT (2.0 Gy fractions). The remaining patients received hyperfractionated RT (1.5-Gy fractions BID). The initial dose of 5-FU was 2.5 mg/m2 given BID. Dose escalation in patient cohorts was scheduled at 2.5-mg/m2 increments, with intrapatient dose escalation permitted. Lymphocyte DPD activity and serum 5-FU and uracil concentrations were monitored during two cycles. DPD activity was completely or nearly completely inactivated in all patients. Sustained, presumed therapeutic concentrations of 5-FU were observed at a dose of 5.0 mg/m2 given BID. Cumulative dose-limiting myelosuppression (both neutropenia and thrombocytopenia) was observed during the fourth and fifth cycles following administration of 5.0 mg/m2 5-FU BID. One patient died of neutropenic sepsis during cycle 4. Other late cycle toxicities included diarrhea, fatigue, and mucositis. Grade 3 mucositis was observed in 4 patients, but no grade 4 mucositis or grade 3 or 4 dermatitis was observed. A second patient death occurred during cycle 1 of treatment. No specific cause of death was identified. The study was subsequently discontinued. Cumulative myelosupression was the significant dose-limiting toxicity of oral 5-FU given with the DPD-inactivator eniluracil on an every-other-week schedule. Clinical radiation sensitization was not observed, based on the absence of dose-limiting mucositis and dermatitis. Alternative dosing schedules need to be examined to determine the most appropriate use of eniluracil and 5-FU as radiation enhancers. (+info)
- A typical case of Ludwig's angina is presented, followed by a review of clinical findings and therapeutic modalities. (biomedsearch.com)
- PURPOSE: This phase II trial is studying sunitinib to see how well it works when given as maintenance therapy in treating patients with stage III or stage IV non-small cell lung cancer which is previously treated with combination chemotherapy. (clinicaltrials.gov)
- Interpersonal accuracy of interventions and the outcome of cognitive and interpersonal therapies for. (biomedsearch.com)
- BACKGROUND: Surfactant therapy is effective in improving the outcome of very preterm infants. (biomedsearch.com)
- After initial therapy with interferon and vinblastine, a relapse occurred and the therapy was changed to sorafenib, followed by sunitinib. (biomedsearch.com)
- Osteonecrosis of the lower jaw appeared 1 year after initial and exclusive therapy with sunitinib. (biomedsearch.com)
- Combined endovascular and vascular surgical therapy of a blister-like distal internal carotid aneurysm in a patient with a right-sided aortic arch. (biomedsearch.com)
- This represents an extremely rare case of a BBA at the left internal carotid artery with a right-sided aortic arch treated with combined endovascular and vascular surgical therapy. (biomedsearch.com)
- Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods. (biomedsearch.com)
- Its only effective treatment is respiratory therapy. (biomedsearch.com)
- It is also called biologic response modifier (BRM) therapy. (doctors-hospital.net)
- The physical exam combined with all of your test results, will help to determine the stage of cancer you have. (doctors-hospital.net)
- Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. (labome.org)
- CONCLUSION: Our results provide experimental evidence that lisinopril administration, when combined with moderate exercise training, is more promising in attenuating cardiac dysfunction than either agent alone in hypertension of a genetic origin. (biomedsearch.com)
- Therefore, all efforts should be made to shorten the total ischemic time, not only for thrombolytic therapy but also for primary angioplasty. (biomedsearch.com)
- The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies. (clinicaltrials.gov)